The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant

Basit Öğe Kaydı
dc.contributor.authorCetin, Hasan
dc.contributor.authorYalaz, Mehmet
dc.contributor.authorAkisu, Mete
dc.contributor.authorKarapinar, Deniz Y.
dc.contributor.authorKavakli, Kaan
dc.contributor.authorKultursay, Nigun
dc.date.accessioned2019-10-27T19:19:04Z
dc.date.available2019-10-27T19:19:04Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.description.abstractPulmonary hemorrhage is a rare but well-known complication in preterm infants. We present a case of massive pulmonary hemorrhage in a 9-day-old male infant, successfully treated with intravenous recombinant activated factor VII (rFVIIa) (NovoSeven; Novo Nordisk). The infant was diagnosed with sepsis-related disseminated intravascular coagulation and required ventilator support for respiratory distress syndrome and blood transfusions due to active bleeding from endotracheal tube. After administration of the second dose of rFVIIa (120 mu g/kg per dose, every 2 h), the active bleeding subsided dramatically and a significant improvement in the oxygenation index was seen 8 h after the third dose of rFVIIa treatment. There were also significant improvements in the prothrombin time, International Normalized Ratio, activated partial thromboplastin time and plasma fibrinogen levels after the third dose of rFVIIa treatment. The infant was discharged on day 82 of life and there was no finding of thrombosis during the hospitalization period. At month 18 of follow-up, there was no morbidity related to the pulmonary and central nervous systems. This case suggests that rFVIIa is effective as an alternative therapy in controlling massive pulmonary hemorrhage of preterm infants.en_US
dc.identifier.doi10.1097/01.mbc.0000220245.20036.2den_US
dc.identifier.endpage216en_US
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue3en_US
dc.identifier.pmid16575260en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage213en_US
dc.identifier.urihttps://doi.org/10.1097/01.mbc.0000220245.20036.2d
dc.identifier.urihttps://hdl.handle.net/11454/38688
dc.identifier.volume17en_US
dc.identifier.wosWOS:000237543500008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofBlood Coagulation & Fibrinolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectpreterm infanten_US
dc.subjectmassive pulmonary hemorrhageen_US
dc.subjectrecombinant activated factor VIIen_US
dc.titleThe use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infanten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu